LOGIN  |  REGISTER
Astria Therapeutics

Privia Health to Enter Washington State

August 01, 2023 | Last Trade: US$21.56 0.48 2.28

ARLINGTON, Va., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) a national physician enablement company, announced it has signed a definitive agreement to enter the state of Washington in partnership with Walla Walla Clinic, a multi-specialty practice with more than 50 providers caring for patients in three locations.

“We are extremely pleased to partner with Walla Walla Clinic as we expand Privia’s west coast presence and continue to execute our strategy of aligning with like-minded providers and practices to offer high quality care to patients across the U.S.,” said Parth Mehrotra, CEO, Privia Health. “Walla Walla Clinic has a highly successful history over its decades of operation, and we look forward to continuing to build on its rich heritage of delivering high quality care in the community.”

“It was essential for us to find the right partner who shares our vision to help build a scaled provider network in Washington while improving access to and affordability of care in our community,” added Mark Haugen, MD, President, Walla Walla Clinic. “We look forward to leveraging Privia Health’s industry expertise, robust technology and services platform, and physician-led governance structure to enable our practice and future provider partners to enhance patient care, reduce administrative burdens, and maintain local autonomy.”

Walla Walla Clinic will serve as the anchor practice for Privia Medical Group — Washington. The transaction is expected to close in the third quarter, and Walla Walla Clinic is expected to be implemented on the Privia Platform by the end of 2023.

Leveraging its data connectivity through a breadth of interoperable solutions and population health expertise to enable care insights and collaboration, Privia Health will provide an alternative to Washington physicians to care for patients across all reimbursement models.

About Privia Health

Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. The Privia Platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.

Cautionary Note Regarding Forward-Looking Statements

This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission (“SEC”), including those under “Risk Factors” therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact

Robert Borchert
SVP, Investor & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 
817.783.4841

Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB